Kangh

Chengdu Kanghua Biological Products Co., Ltd. (hereinafter referred to as "Kanghua Bio") was established in 2004 and is located in Chengdu National Economic and Technological Development Zone, covering an area of approximately 30,000 square meters. Kanghua Bio is equipped with an animal testing center and GMP production workshops for bacterial and viral vaccines with advanced technical levels. Its main business includes the production, sales, research, development, and technical services of preventive biological products. Its current product portfolio includes "ACYW135 Meningococcal Polysaccharide Vaccine" (brand name: Maixin) and "Lyophilized Human Rabies Vaccine (Human Diploid Cells)" (brand name: HDCV).Since its establishment, Kanghua Bio has been awarded honors such as "Postdoctoral Innovation Practice Base," "Sichuan Province Constructive Innovation Enterprise Cultivation Enterprise," and "Sichuan Province Outstanding Integrity Demonstration Unit" by the Personnel Department and Science and Technology Department, among others. It has also passed the GMP certification from the National Medical Products Administration. In recent years, Kanghua Bio has undertaken several scientific and technological projects, with over a hundred technical applications filed for patent protection.Kanghua Bio actively recruits highly educated talent, with more than 80% of its employees holding an associate degree or higher. Most of its production and R&D personnel have more than five years of experience in the biologics industry. The company owns advanced production, R&D, and testing equipment, as well as comprehensive analytical detection and experimental facilities, demonstrating strong R&D capabilities that fully meet the needs of large-scale production and quality requirements.Several of the company's R&D projects have received support from government science and technology special funds. As the first independently developed product launched into the market, the "ACYW135 Meningococcal Polysaccharide Vaccine" has gained an excellent reputation among customers due to its superior quality and has been exported overseas, laying the foundation for Kanghua Bio’s high-quality brand image. The "Lyophilized Human Rabies Vaccine (Human Diploid Cells)" successfully entered the market in 2014, marking a historic breakthrough as the first human diploid cell rabies vaccine produced and sold in mainland China, with expected contributions to rabies prevention and control efforts in China and Asia. Additionally, Kanghua Bio has ongoing R&D projects such as the "Lyophilized Human Rabies Vaccine (Human Diploid Cells, Immobilized Bioreactor Culture)."